MINI FUTURE LONG - GILEAD SCIENCES | Real-time Bid/Ask 04:37:42 2024-07-11 am EDT | ||
| 1.05 EUR / 1.08 EUR | +2.40% |
|
| 1 month | +44.44% | ||
| 3 months | -3.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.06 | +1.92% |
| 24-07-10 | 1.04 | +7.22% |
| 24-07-09 | 0.97 | +3.19% |
| 24-07-08 | 0.94 | +8.05% |
| 24-07-05 | 0.87 | +2.35% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:52 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PR9F6Y |
| ISIN | DE000PR9F6Y9 |
| Date issued | 2017-09-01 |
| Strike | 57.26 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.44 € |
|---|---|
| Lowest since issue | 0.35 € |
| Spread | 0.03 € |
| Spread % | 2.78% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.75
USD
Average target price
83.23
USD
Spread / Average Target
+21.06%
- Stock Market
- Certificates
- Certificat
